222 related articles for article (PubMed ID: 36192668)
1. Association between physical activity and health-related quality of life: time to deterioration model analysis in lung adenocarcinoma.
Zhuang J; Liu Y; Xu X; Cai Y; Liu M; Chen Z; Yang S; Lin J; Hu Z; Kang M; Lin M; He F
J Cancer Surviv; 2023 Dec; 17(6):1769-1779. PubMed ID: 36192668
[TBL] [Abstract][Full Text] [Related]
2. Longitudinal analysis of quality of life in primary lung cancer patients with chlamydia pneumoniae infection: a time-to-deterioration model.
Chen Z; Zhuang J; Liu M; Xu X; Liu Y; Yang S; Xie J; Lin N; Lai F; He F
BMC Pulm Med; 2024 Jan; 24(1):36. PubMed ID: 38233781
[TBL] [Abstract][Full Text] [Related]
3. The EORTC QLQ-LC13: a modular supplement to the EORTC Core Quality of Life Questionnaire (QLQ-C30) for use in lung cancer clinical trials. EORTC Study Group on Quality of Life.
Bergman B; Aaronson NK; Ahmedzai S; Kaasa S; Sullivan M
Eur J Cancer; 1994; 30A(5):635-42. PubMed ID: 8080679
[TBL] [Abstract][Full Text] [Related]
4. Pembrolizumab alone or with chemotherapy for recurrent or metastatic head and neck squamous cell carcinoma: Health-related quality-of-life results from KEYNOTE-048.
Rischin D; Harrington KJ; Greil R; Soulières D; Tahara M; de Castro G; Psyrri A; Braña I; Neupane P; Bratland Å; Fuereder T; Hughes BGM; Mesía R; Ngamphaiboon N; Rordorf T; Ishak WZW; Hong RL; Mendoza RG; Jia L; Chirovsky D; Norquist J; Jin F; Burtness B
Oral Oncol; 2022 May; 128():105815. PubMed ID: 35381576
[TBL] [Abstract][Full Text] [Related]
5. Establishing Meaningful Change Thresholds in Patient-Reported Outcomes Among Patients With Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer in ALTA-1L Trial.
Beaumont JL; Lin HM; Goodman E; Yu H; Geiger A; Hudgens S
Value Health; 2024 Feb; 27(2):182-189. PubMed ID: 37951539
[TBL] [Abstract][Full Text] [Related]
6. Quality of life with first-line pembrolizumab for PD-L1-positive advanced gastric/gastroesophageal junction adenocarcinoma: results from the randomised phase III KEYNOTE-062 study.
Van Cutsem E; Valderrama A; Bang YJ; Fuchs CS; Shitara K; Janjigian YY; Qin S; Larson TG; Shankaran V; Stein S; Norquist JM; Kher U; Shah S; Alsina M
ESMO Open; 2021 Aug; 6(4):100189. PubMed ID: 34371381
[TBL] [Abstract][Full Text] [Related]
7. Health-related Quality of Life in the Phase III LUME-Colon 1 Study: Comparison and Interpretation of Results From EORTC QLQ-C30 Analyses.
Lenz HJ; Argiles G; Yoshino T; Lonardi S; Falcone A; Limón ML; Sobrero A; Hastedt C; Peil B; Voss F; Griebsch I; Van Cutsem E
Clin Colorectal Cancer; 2019 Dec; 18(4):269-279.e5. PubMed ID: 31628043
[TBL] [Abstract][Full Text] [Related]
8. Health-related quality of life in patients with microsatellite instability-high or mismatch repair deficient metastatic colorectal cancer treated with first-line pembrolizumab versus chemotherapy (KEYNOTE-177): an open-label, randomised, phase 3 trial.
Andre T; Amonkar M; Norquist JM; Shiu KK; Kim TW; Jensen BV; Jensen LH; Punt CJA; Smith D; Garcia-Carbonero R; Sevilla I; De La Fouchardiere C; Rivera F; Elez E; Diaz LA; Yoshino T; Van Cutsem E; Yang P; Farooqui M; Le DT
Lancet Oncol; 2021 May; 22(5):665-677. PubMed ID: 33812497
[TBL] [Abstract][Full Text] [Related]
9. Health-related quality of life in the randomized phase III trial of brigatinib vs crizotinib in advanced ALK inhibitor-naive ALK + non-small cell lung cancer (ALTA-1L).
Garcia Campelo MR; Lin HM; Zhu Y; Pérol M; Jahanzeb M; Popat S; Zhang P; Camidge DR
Lung Cancer; 2021 May; 155():68-77. PubMed ID: 33744781
[TBL] [Abstract][Full Text] [Related]
10. Health-related quality of life in long-term survivors of unresectable locally advanced non-small cell lung cancer.
Ran J; Wang J; Bi N; Jiang W; Zhou Z; Hui Z; Liang J; Feng Q; Wang L
Radiat Oncol; 2017 Dec; 12(1):195. PubMed ID: 29197373
[TBL] [Abstract][Full Text] [Related]
11. Impact of neoadjuvant chemoradiotherapy on health-related quality of life in long-term survivors of esophageal or junctional cancer: results from the randomized CROSS trial.
Noordman BJ; Verdam MGE; Lagarde SM; Shapiro J; Hulshof MCCM; van Berge Henegouwen MI; Wijnhoven BPL; Nieuwenhuijzen GAP; Bonenkamp JJ; Cuesta MA; Plukker JTM; Spillenaar Bilgen EJ; Steyerberg EW; van der Gaast A; Sprangers MAG; van Lanschot JJB;
Ann Oncol; 2018 Feb; 29(2):445-451. PubMed ID: 29126244
[TBL] [Abstract][Full Text] [Related]
12. Measuring the Time to Deterioration for Health-Related Quality of Life in Patients With Metastatic Breast Cancer Using a Web-Based Monitoring Application: Longitudinal Cohort Study.
Brusniak K; Feisst M; Sebesteny L; Hartkopf A; Graf J; Engler T; Schneeweiss A; Wallwiener M; Deutsch TM
JMIR Cancer; 2021 Oct; 7(4):e25776. PubMed ID: 34636732
[TBL] [Abstract][Full Text] [Related]
13. Cardiovascular health-related quality of life in cancer: a prospective study comparing the ESC HeartQoL and EORTC QLQ-C30 questionnaire.
Anker MS; Potthoff SK; Lena A; Porthun J; Hadzibegovic S; Evertz R; Denecke C; Fröhlich AK; Sonntag F; Regitz-Zagrosek V; Rosen SD; Lyon AR; Lüscher TF; Spertus JA; Anker SD; Karakas M; Bullinger L; Keller U; Landmesser U; Butler J; von Haehling S
Eur J Heart Fail; 2023 Sep; 25(9):1635-1647. PubMed ID: 37369985
[TBL] [Abstract][Full Text] [Related]
14. Reference values for the EORTC QLQ-C30 in patients with advanced stage Hodgkin lymphoma and in Hodgkin lymphoma survivors.
Vachon H; Mierzynska J; Taye M; Pe M; Coens C; Martinelli F; Fortpied C; Flechtner HH; Vestmoe Maraldo M; Hutchings M; Meijnders P; Aleman B; Lugtenburg P; Spina M; André M; Hertzberg M; Briones J; Bottomley A;
Eur J Haematol; 2021 May; 106(5):697-707. PubMed ID: 33570765
[TBL] [Abstract][Full Text] [Related]
15. Quality of life with cemiplimab plus chemotherapy for first-line treatment of advanced non-small cell lung cancer: Patient-reported outcomes from phase 3 EMPOWER-Lung 3.
Makharadze T; Quek RGW; Melkadze T; Gogishvili M; Ivanescu C; Giorgadze D; Dvorkin M; Penkov K; Laktionov K; Nemsadze G; Nechaeva M; Rozhkova I; Kalinka E; Gessner C; Moreno-Jaime B; Passalacqua R; Konidaris G; Rietschel P; Gullo G
Cancer; 2023 Jul; 129(14):2256-2265. PubMed ID: 37151113
[TBL] [Abstract][Full Text] [Related]
16. Does it matter how we evaluate HRQOL? Longitudinal comparison of the EORTC QLQ-C30/QLQ-OG25 and FACT-E.
Darling GE; Sulman J; Espin-Garcia O; Trudel JG; Atenafu EG; Kidane B
J Cancer Surviv; 2021 Aug; 15(4):641-650. PubMed ID: 33106994
[TBL] [Abstract][Full Text] [Related]
17. Longitudinal health-related quality of life analysis in oncology with time to event approaches, the STATA command qlqc30_TTD.
Bascoul-Mollevi C; Savina M; Anota A; Barbieri A; Azria D; Bonnetain F; Gourgou S
Comput Methods Programs Biomed; 2018 May; 158():153-159. PubMed ID: 29544781
[TBL] [Abstract][Full Text] [Related]
18. Quality of life of lung cancer patients: validation of the Taiwan Chinese version of the EORTC QLQ-C30 and QLQ-LC13.
Chie WC; Yang CH; Hsu C; Yang PC
Qual Life Res; 2004 Feb; 13(1):257-62. PubMed ID: 15058806
[TBL] [Abstract][Full Text] [Related]
19. Health-related quality of life in patients with lung cancer: validation of the Mexican-Spanish version and association with prognosis of the EORTC QLQ-LC13 questionnaire.
Arrieta Ó; Núñez-Valencia C; Reynoso-Erazo L; Alvarado S; Flores-Estrada D; Angulo LP; Oñate-Ocaña LF
Lung Cancer; 2012 Jul; 77(1):205-11. PubMed ID: 22387006
[TBL] [Abstract][Full Text] [Related]
20. Health-related quality of life and treatment modality among esophageal squamous cell carcinoma survivors: A prospective study using time to deterioration model analysis.
Liu S; Lin Z; Lin J; Chen H; Xie Q; Rao W; Chen Y; Yu K; Hu Z
J Surg Oncol; 2021 Jan; 123(1):156-163. PubMed ID: 33126290
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
